Avadel Pharmaceuticals PLC Cash Flow Conversion Efficiency
Avadel Pharmaceuticals PLC cash flow conversion efficiency. Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has a cash flow conversion efficiency ratio of 0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($23.26 Million) by net assets ($98.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Avadel Pharmaceuticals PLC (1996–2024)
Cash flow conversion efficiency of Avadel Pharmaceuticals PLC from 1996 to 2024. This chart illustrates how Avadel Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AVDL stock price and chart for real-time trading data and today's change.
Avadel Pharmaceuticals PLC Cash Flow Conversion Ratio Explained
Avadel Pharmaceuticals PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Avadel Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Also see AVDL market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compania Cervecerias Unidas SA
SN:CCU
|
-0.020x |
|
John Wiley & Sons
NYSE:WLY
|
0.240x |
|
Íslandsbanki hf.
IC:ISB
|
0.079x |
|
Frontken Corporation Bhd
KLSE:0128
|
0.036x |
|
First Commonwealth Financial
NYSE:FCF
|
0.055x |
|
Jushri Technologies Inc Class A
SHE:300762
|
-0.010x |
|
Carborundum Universal Limited
NSE:CARBORUNIV
|
0.029x |
|
Bayside Land Corporation Ltd
TA:BYSD
|
0.039x |
Annual Cash Flow Conversion Efficiency for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual cash flow conversion efficiency of Avadel Pharmaceuticals PLC from 1996 to 2024. Review Avadel Pharmaceuticals PLC (AVDL) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.85 Million | $-46.91 Million | -0.635x | +56.63% |
| 2023-12-31 | $87.74 Million | $-128.51 Million | -1.465x | -144.05% |
| 2022-12-31 | $-21.14 Million | $-70.30 Million | 3.325x | +436.50% |
| 2021-12-31 | $78.24 Million | $-77.31 Million | -0.988x | -228.99% |
| 2020-12-31 | $162.27 Million | $-48.73 Million | -0.300x | -122.88% |
| 2019-12-31 | $-29.20 Million | $-38.33 Million | 1.313x | +104.41% |
| 2018-12-31 | $2.78 Million | $-82.72 Million | -29.754x | -15200.73% |
| 2017-12-31 | $84.56 Million | $16.66 Million | 0.197x | -56.14% |
| 2016-12-31 | $42.07 Million | $18.90 Million | 0.449x | -63.83% |
| 2015-12-31 | $67.86 Million | $84.29 Million | 1.242x | +391.22% |
| 2014-12-31 | $24.89 Million | $-10.62 Million | -0.427x | -119.62% |
| 2013-12-31 | $-9.51 Million | $-20.68 Million | 2.174x | +386.55% |
| 2012-12-31 | $30.50 Million | $-23.14 Million | -0.759x | -118.93% |
| 2011-12-31 | $29.79 Million | $-10.32 Million | -0.346x | -130.51% |
| 2010-12-31 | $36.30 Million | $-5.46 Million | -0.150x | -182.29% |
| 2009-12-31 | $44.86 Million | $8.20 Million | 0.183x | +218.11% |
| 2008-12-31 | $48.55 Million | $-7.51 Million | -0.155x | +56.09% |
| 2007-12-31 | $54.63 Million | $-19.24 Million | -0.352x | +13.76% |
| 2006-12-31 | $73.03 Million | $-29.83 Million | -0.408x | -82.54% |
| 2005-12-31 | $86.65 Million | $-19.39 Million | -0.224x | -529.51% |
| 2004-12-31 | $116.76 Million | $-4.15 Million | -0.036x | -126.76% |
| 2003-12-31 | $92.06 Million | $12.23 Million | 0.133x | -81.40% |
| 2002-12-31 | $12.29 Million | $8.77 Million | 0.714x | +292.55% |
| 2001-12-31 | $7.51 Million | $-2.78 Million | -0.371x | +28.24% |
| 2000-12-31 | $10.88 Million | $-5.62 Million | -0.517x | -10.51% |
| 1999-12-31 | $9.07 Million | $-4.24 Million | -0.468x | -1.55% |
| 1998-12-31 | $17.79 Million | $-8.19 Million | -0.460x | +26.03% |
| 1997-12-31 | $14.30 Million | $-8.90 Million | -0.622x | -242.31% |
| 1996-12-31 | $23.10 Million | $-4.20 Million | -0.182x | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more